[go: up one dir, main page]

WO2025051941A1 - Procédé de production d'une composition nutritionnelle parentérale ou entérale, système conçu pour celui-ci, et produit informatique - Google Patents

Procédé de production d'une composition nutritionnelle parentérale ou entérale, système conçu pour celui-ci, et produit informatique Download PDF

Info

Publication number
WO2025051941A1
WO2025051941A1 PCT/EP2024/074968 EP2024074968W WO2025051941A1 WO 2025051941 A1 WO2025051941 A1 WO 2025051941A1 EP 2024074968 W EP2024074968 W EP 2024074968W WO 2025051941 A1 WO2025051941 A1 WO 2025051941A1
Authority
WO
WIPO (PCT)
Prior art keywords
data processing
processing system
formulation
components
stability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/074968
Other languages
German (de)
English (en)
Inventor
Michael Hock
Steffen Roser
Christian Hermann HENNECKE
Henrik Rasmussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Kabi Deutschland GmbH
Original Assignee
Fresenius Kabi Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Deutschland GmbH filed Critical Fresenius Kabi Deutschland GmbH
Publication of WO2025051941A1 publication Critical patent/WO2025051941A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/002—Compounding apparatus specially for enteral or parenteral nutritive solutions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/60—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets

Definitions

  • the invention relates to a method for producing a parenteral or enteral nutritional composition using an automated filling system.
  • the invention further relates to a system designed to carry out the method and to a computer program product.
  • nutritional compositions for parenteral or enteral nutrition can be prepared using a recipe tailored to the specific patient. From this recipe, a formulation is created in which the components of the nutritional composition and their respective amounts are clearly defined.
  • Automated filling systems so-called compounders, are used to fill the components into a target container.
  • a compounder can comprise a pump and a transfer set with a plurality of valves.
  • the transfer set can be connected to a plurality of source containers.
  • the compounder can fill the target container with the various components of the nutritional composition according to a formulation.
  • a compounder is known, for example, from the published patent application WO 2017/158032 A1.
  • the basic components of such a nutritional composition are a glucose-containing liquid, a lipid-containing liquid, and an amino acid-containing liquid.
  • Liquids that additionally contain vitamins and/or trace elements, for example, can be added using the compounder, adapted to the respective formulation.
  • one of the source containers usually contains a universal liquid, e.g., water, which is transferred to the destination container.
  • the universal liquid is used to rinse the transfer set between switching the withdrawal from one source container to another.
  • the published patent application WO 01/39874 A1 shows a method which serves to reduce the number of such rinsing cycles.
  • the pharmacist is usually responsible for ensuring compliance with the recipe. This means that, based on a recipe, a formulation is created that contains the clearly identifiable components of the respective nutritional composition.
  • the formulation usually also includes the mixing sequence of the components.
  • the overall composition influences the chemical stability of the mixture, its physical stability (e.g., in the case of emulsions), and its shelf life.
  • the compatibility and stability of the individual components of a nutritional composition which the pharmacist can refer to manually.
  • the invention in contrast, is based on the object of reducing the aforementioned disadvantages of the prior art.
  • the invention aims to provide a method for producing an enteral or parenteral nutritional composition that is as simple as possible and offers a high level of safety.
  • the object of the invention is already achieved by a method for producing a parenteral or enteral nutritional composition, by a system for producing an enteral or parenteral nutritional composition and by a computer program product according to one of the independent claims.
  • Preferred embodiments and developments of the invention can be found in the subject matter of the dependent claims, the description and the drawings.
  • the invention relates to a process for the preparation of a parenteral or enteral nutritional composition, which comprises the following steps:
  • a formulation is understood to be a compilation of components according to quantity and clearly identifiable type of component, such as the exact drug name.
  • the formulation can be prepared by the pharmacist based on the recipe.
  • the formulation may contain, in whole or in part, only information on specific substances in the desired quantity.
  • the pharmacist selects suitable drug compositions, particularly components of parenteral or enteral nutrition solutions, from which the formulation is created.
  • the recipe already contains a clear identification of the components, so that a formulation is already created by creating the recipe.
  • the recipe may specify the amount of a trace element, such as potassium.
  • a trace element such as potassium
  • potassium is a solid that cannot be added in its pure form to the nutritional composition.
  • the pharmacist selects a suitable potassium solution, such as a potassium chloride or potassium phosphate solution from a specific manufacturer, to incorporate the desired amount of potassium.
  • the recipe may already specify a uniquely identifiable potassium solution from a specific manufacturer.
  • a first data processing system is used, to which the pharmacist in particular has access.
  • the first data processing system comprises a database in which unique identifications of components of a nutritional composition are stored.
  • the first data processing system can access the first database and check whether a unique identification exists and assign it to the component based on a trade name, a drug number, such as a PZN number, securPharm or a National Drug Code.
  • the unique identification may, for example, be a sequence of numbers and/or letters assigned to a component of the food composition.
  • Components that, for example, are named differently in different countries or have a different drug number can be assigned to a single identification.
  • the first data processing system can generate a corresponding notice for the user so that he or she has the option, for example, to use another component with the same relevant substances.
  • the first data processing system transmits the approved formulation to a second data processing system.
  • the test is therefore carried out in two stages, with the first data processing system at least checking whether the components are uniquely identified.
  • first and/or second data processing system Release within the meaning of the invention by the first and/or second data processing system is understood to mean checking the criteria stored in the first or second data processing system and their evaluation. Consent for the compounder to mix the nutritional composition, i.e., release for production, is given by the user, i.e., usually by the pharmacist.
  • the second data processing system is preferably a data processing system on which the user of the first data processing system cannot change at least the data stored in a second database of the second data processing system.
  • the user of the first data processing system therefore only has write access to the first database of the first data processing system, not but to the second database of the second data processing system .
  • the second data processing system can thus be easily administered and maintained without the involvement of the user of the first data processing system.
  • the second data processing system comprises a second database in which stability and/or compatibility criteria of the components are stored.
  • the stability criteria of components and of the mixture with other components include in particular the shelf life of the corresponding nutritional composition.
  • the stored compatibility criteria determine whether and in what quantity the respective components can be mixed with each other without causing undesirable reactions, for example chemical reactions.
  • the relevant information is stored in the second database.
  • the second data processing system can rely on the unique identification of the respective components.
  • the formulation tested for stability and/or compatibility by the second data processing system can be released.
  • the second data processing system transmits the release to the first data processing system.
  • the user of the first data processing system thus receives at least the release from the second data processing system and can then initiate the filling of the target container if the corresponding release is available.
  • the security of the system is increased by the fact that the user preferably does not have write access to the second database of the second data processing system. Compared to manual review of studies, security is increased by the automated testing of stability and/or compatibility by the second data processing system.
  • the control of the automated filling system to initiate the filling process can be carried out in particular via the first data processing system.
  • the first data processing system transmits the formulation to the automated filling system.
  • the transmission is preferably initiated by the user, e.g., by an input on the client.
  • the automated filling system is designed, in particular, as a compounder with a dosing pump.
  • a transfer set via which liquid is withdrawn from the source container and pumped into the target container, can be connected to the compounder.
  • the compounder can therefore comprise all combinations of features disclosed in this document.
  • the second data processing system transmits to the first data processing system a data record which, in addition to the release, also contains the wording.
  • This can be a write-protected, encrypted data record in which the wording is stored together with the release by the second data processing system.
  • the first data processing system at least partially suggests the formulation on the basis of a recipe entered into the first data processing system.
  • the recipe may only include the quantities of certain substances in the nutritional composition.
  • the recipe can be entered into the first data processing system, whereby the first data processing system then suggests components based on the desired substances, for which a unique identification is stored.
  • the user of the first data processing system now selects a component for which a unique identification exists. From this, the formulation is formed.
  • the first data processing system checks a limit value based on data stored in the first database relating to the dosage of a component of the formulation and/or relating to a volume of the formulation.
  • the first data processing system can check in advance whether the desired volume is compatible with the selected target container.
  • the first data processing system can check, for example, whether the formulation contains at least one substance for which a minimum or maximum quantity is exceeded or not met.
  • the first data processing system can check, for example, based on the patient's weight, whether a maximum amount of the volume to be transferred has been exceeded.
  • the first data processing system can generate a warning for the user and the formulation will not be released.
  • the threshold value is checked, in particular, based on patient-specific data entered into the first data processing system. This may include, in particular, the patient's weight, gender, and/or age.
  • the first data processing system can, in particular, access the first database to check whether the target container is sufficiently dimensioned for the desired nutritional composition, whether the mixing sequence is maintained in such a way that no undesirable chemical and/or physical reactions occur and/or whether the total volume of the target container is not too high for the respective patient.
  • the step of assigning a unique identification to the components by the first data processing system comprises the conversion of a drug number or a Drug name of the component in the unique identification.
  • the first data processing system may contain a conversion database in which national authorisation numbers, such as PZN number or National Drug Code and/or national trade names, are assigned to a unique identification which is used by the second data processing system during the check.
  • national authorisation numbers such as PZN number or National Drug Code and/or national trade names
  • the second data processing system can dispense with the use of such a conversion database, i.e. for the assignment of the individual components, only the unique identifications of the respective components are stored in the second database of the second data processing system.
  • the checking of the mixing sequence of the components is carried out by the first data processing system, particularly preferably only by the first data processing system.
  • the check by the first and/or second data processing system comprises a check of the type of the target container.
  • the first data processing system checks whether the volume of the selected target container is compatible with the volume of the formulation.
  • the second data processing system checks, for example, the extent to which the target container is compatible with the components of the formulation in terms of material and other design so that they are stable for a sufficient period of time.
  • the second data processing system can generate a shelf life indication and/or a storage condition.
  • This is preferably generated taking into account the type of target container.
  • the second data processing system can, for example, display together with the release how long and at what temperature the target container can be stored and, in particular, whether it needs to be protected from light, etc.
  • the second data processing system if the second data processing system fails to check the formulation, the second data processing system generates a proposed change to the formulation and forwards this to the first data processing system.
  • study data stored in the second database can be used to check which minimum or maximum amount and/or concentration of a particular component may be present in the food composition. If a minimum quantity is not met or a maximum quantity is exceeded, the second data processing system can prepare a corresponding correction proposal and transmit it to the first data processing system.
  • the user can then decide whether to accept the proposed change.
  • the first data processing system communicates with the second data processing system via a network, preferably the Internet.
  • Communication is preferably encrypted.
  • the target containers and components are assigned based on unique identification.
  • the first data processing system is provided in such a way that it comprises a backend server that communicates, on the one hand, with at least one client for inputting the recipe and/or formulation and, on the other hand, with the second data processing system.
  • the client and backend server can be located on the same computer system.
  • the client can be configured as a terminal of the backend server.
  • the first data processing system thus serves as an interface for the user using the client.
  • the release can be transmitted by the second data processing system to the client via the backend server.
  • the transmission of the formulation to the automated filling system can also be initiated via the client. This is preferably done via the backend server.
  • the first database which the backend server uses to check the formulation, is preferably integrated in such a way that the second data processing system has no access to the first database.
  • Communication within the network can be via TCP/IP, for example. Transmission can take place via a bidirectional interface from the first data processing system to the automated filling system and/or second data processing system.
  • the data format used can be ASCII, XML or JSON, for example.
  • the first data processing system preferably does not allow external or active domain user access to the database.
  • the first data processing system can thus be designed to be closed.
  • access to the first data processing system can be provided by other Active Domain users, thus enabling central administration.
  • the first database is preferably protected against tampering by encryption. Encryption is activated by the database administrator, and a key for access is generated and managed in the system.
  • the second database contains
  • the user of the first data processing system thus receives easy access to study data that are relevant for the selected formulation.
  • a single-chamber container or a multi-chamber container can be provided as the target container.
  • the target container can, in particular, be designed as a bag.
  • the first and/or second data processing system considers whether the components are mixed in a single-chamber container or whether they are distributed among the various chambers of a multi-chamber container.
  • the invention further relates to a system which is designed to carry out the method described above.
  • the system comprises in particular the first and the second data processing system as well as software which controls the system in such a way that it operates in accordance with the method described above.
  • the system is designed to assign a unique identification to the components of a formulation of an enteral or parenteral nutritional composition, wherein the unique Identification is stored in a first database of the system, and wherein the system is designed, if a unique identification is assigned to the components, to release the formulation and to transmit it to a second data processing system, which is designed to check the formulation for stability and/or compatibility of the components and to release the formulation if the stability and/or compatibility criteria are met, and wherein the system is designed to receive the release of the second data processing system and to display the release of the second data processing system to a user.
  • the first data processing system is designed to transmit the formulation checked and approved by the second data processing system to an automated filling system, in particular after the user has given his consent.
  • the invention relates to a computer product which comprises instructions which, when a program is executed, carry out the above-mentioned method steps.
  • the invention further relates to a computer program product comprising instructions that cause a first data processing system to assign a unique identification to the components of a formulation of an enteral or parenteral nutritional composition and, if a unique identification is assigned to the components, to release the formulation and to transmit it to a second data processing system that is designed to check the formulation for stability and/or compatibility of the components. and release the formulation if the stability and/or compatibility criteria are met, and receive the release of the second data processing system and indicate the release of the second data processing system to a user.
  • the computer program product also comprises instructions to cause the first data processing system to transmit the formulation checked and approved by the second data processing system to an automated filling system, in particular after the user's consent.
  • Fig. 1 is a flowchart of an embodiment of a method according to the invention.
  • Fig. 2 is a flow diagram of an embodiment of a method according to the invention.
  • Fig. 3 shows an embodiment of a system for carrying out a method according to the invention.
  • screenshots are used to explain in more detail how a recipe is entered until it is released by the second data processing system.
  • Fig. 5a to Fig. 5c show a corresponding alternative embodiment in which no release takes place.
  • FIG. 1 to 3 serve to illustrate an embodiment of a system according to the invention (Fig. 3) on which a method according to the invention (Fig. 1 and Fig. 2) runs.
  • Fig. 1 is a flowchart of an embodiment of a method according to the invention.
  • the user who has access to the first data processing system 10 via a client lla-llc, enters a recipe, the mixing sequence and the type of desired target container 33 for an enteral or parenteral nutritional composition 101.
  • the user can enter desired substances that should be added to the nutritional composition.
  • the first computer system 10 then suggests a component containing this substance.
  • the first data processing system 10 can, among other things, also make the display dependent on whether the respective component is available.
  • the user then specifies the type of desired target container 33. For example, the material of the target container 33 is defined, whether it is a foil bag, and/or whether it is a multi-chamber container.
  • the user can also enter patient-specific data, in particular the patient's weight, age and/or gender.
  • the first Data processing system 10 allows the user to create at least one electronic formulation of components for the nutritional composition in which each component, including the target container 33, is uniquely defined 102.
  • a unique identification is assigned to the trade name of a medicinal product or a regional pharmaceutical number.
  • the first computer system 10 more precisely the backend server 12, checks the formulation including the type of the desired target container 33 at least to determine whether each component, including the target container 33, is assigned a unique identification 103.
  • the first data processing system 10 preferably also checks the formulation for criteria such as mixing order, maximum/minimum volume and/or limit values for certain substances present in the food composition.
  • the formulation will not be released, but the user will be notified of the failed release on the lla-llc client.
  • the formulation is forwarded to a second data processing system 20 104.
  • the second data processing system 20 now checks the components of the formulation for chemical and/or physical stability and compatibility. In the event of a failed release, this is also displayed on the client lla-llc. The transmission is carried out by the second data processing system 20 via the backend server 12.
  • the second data processing system 20 accesses a second database 21 to which the first data processing system 10 has at least no write access 105.
  • the release is forwarded to the first data processing system 10, more precisely to the backend server 12, and displayed 106 on the client lla-llc.
  • the released formulation can now be transferred to the compounder 30 and the target container 33 can be filled.
  • the transmission of the formulation is preferably initiated via the client lla-llc of the first data processing system 10.
  • Fig. 2 is a flow diagram of the method according to the invention, which in this representation is divided into the levels marked 1 - 4.
  • “1” indicates the location where the prescription is created, for example, the hospital where the prescription is created.
  • “2” indicates the processes that take place at the pharmacist's office.
  • "3” indicates the automated filling system (production), and "4" indicates the second data processing system 20.
  • the pharmacist creates an electronic formulation proposal with the aid of the first data processing system 10.
  • the first data processing system 10 checks the formulation and releases it.
  • Each component including the target container 33, contains a unique identification.
  • This data set which contains the components, their quantity and the type of target container 33 along with a unique identification, is forwarded from the first data processing system 10 to the second data processing system 20.
  • the second data processing system 20 checks the chemical and physical stability of the components of the formulation relative to one another using a second database 21 in which compatibility and stability criteria are stored.
  • the target container 33 is released and delivered.
  • the compounder 30 does not release the target container 33. In this case, the system reverts, so the formulation must be released again, checked for chemical stability, and filled into the target container.
  • Fig. 3 is a schematic representation of a system for carrying out the method according to the invention.
  • the first data processing system 10 has no write permissions on the second data processing system 20.
  • Such a compounder 30 comprises a pump and a valve unit 31, via which the withdrawal from the source containers 32a - 32n is controlled.
  • the valve unit 31 can be part of a so-called transfer set, which comprises the hoses to the source containers 32a - 32n and the at least one hose to the target container 33.
  • the target container 33 can be either a single-chamber or a multi-chamber container.
  • a third data processing system 40 is also present, to which the first data processing system 10 has read access.
  • the first data processing system 10 can thus receive data from the third data processing system 40.
  • specific formulations can be retrieved and used from the third data processing system.
  • the user can enter a recipe into the first data processing system 10.
  • the input is made on the client lla-llc.
  • the first data processing system 10 can access the first database 13 and create a recipe from it, which contains a unique identification of the respective component.
  • An individual identification code is used for each component, which, in this exemplary embodiment, is generated by uniquely assigning the trade name entered in the respective national language to a component.
  • the user can also enter the type of target container 33, the target volume of the components and the patient's body weight.
  • Fig. 4b there is a unique assignment for each component, so that the formulation can be forwarded to the second data processing system 20. This is graphically indicated by a check mark in this embodiment.
  • Fig. 4c shows the release of the formulation by the second data processing system 20, which is forwarded to the client lla-llc of the first data processing system 10.
  • the system In addition to the actual release, the system also provides a link to a study.
  • the filling of the target container 33 can now be released.
  • the input into the first data processing system 10 is identical, ie the user, in particular the pharmacist, first enters the recipe in the national language, then the first data processing system 10 supports the creation of a Formulation where each component has a unique identification, as shown in Fig. 5b.
  • the maximum concentration of a component for a pediatric nutritional composition is exceeded.
  • the calcium concentration in the composition is exceeded.
  • the second data processing system 20 not only informs the user of the failed release, but also recommends reducing the amount of a component and reducing the substance calcium.
  • the user can change both the recipe and the formulation created from the recipe on the first data processing system 10 in order to then achieve release in a repeat step.
  • the user can modify both the recipe and/or the formulation created from the recipe on the second data processing system 20 in order to then achieve approval in a repeat step.
  • the modified recipe or formulation is transmitted back from the second data processing system 20 to the first data processing system 10 and adopted, particularly after user approval.
  • the invention has made it possible to provide a method by which an enteral or parenteral nutritional composition can be produced in a simple manner and with a high degree of safety.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

L'invention concerne un procédé de production d'une composition nutritionnelle parentérale ou entérale, comprenant les étapes consistant à : - fournir une formulation qui contient une pluralité de composants de la composition nutritionnelle ; -attribuer une identification non ambiguë aux composants à l'aide d'un premier système de traitement de données, l'identification non ambiguë étant stockée dans une première base de données du premier système de traitement de données ; - effacer la formulation au moyen du premier système de traitement de données si l'identification non ambiguë du composant est présente ; - transmettre la formulation effacée, au moyen du premier système de traitement de données, à un second système de traitement de données ; - vérifier la formulation transmise au moyen du second système de traitement de données, la composition de la pluralité de composants de la composition nutritionnelle étant vérifiée pour la stabilité et la compatibilité, et les critères de stabilité et de compatibilité étant stockés dans une seconde base de données du second système de traitement de données ; - effacer la formulation vérifiée par le second système de traitement de données pour la stabilité et la compatibilité si les critères de stabilité et de compatibilité sont satisfaits ; - transmettre l'effacement du second système de traitement de données au premier système de traitement de données ; et - remplir un récipient cible avec la composition nutritionnelle selon la formulation au moyen d'un système de remplissage automatisé.
PCT/EP2024/074968 2023-09-08 2024-09-06 Procédé de production d'une composition nutritionnelle parentérale ou entérale, système conçu pour celui-ci, et produit informatique Pending WO2025051941A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23196249 2023-09-08
EP23196249.9 2023-09-08

Publications (1)

Publication Number Publication Date
WO2025051941A1 true WO2025051941A1 (fr) 2025-03-13

Family

ID=88016200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/074968 Pending WO2025051941A1 (fr) 2023-09-08 2024-09-06 Procédé de production d'une composition nutritionnelle parentérale ou entérale, système conçu pour celui-ci, et produit informatique

Country Status (1)

Country Link
WO (1) WO2025051941A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6070761A (en) * 1997-08-22 2000-06-06 Deka Products Limited Partnership Vial loading method and apparatus for intelligent admixture and delivery of intravenous drugs
WO2001039874A1 (fr) 1999-12-03 2001-06-07 Baxter International Inc. Procede et appareil regulant la strategie de confection de melanges pharmaceutiques
US20020077857A1 (en) * 2000-12-15 2002-06-20 Paul Seelinger Local medication scan code date repository (LMSCDR)
EP1616550A1 (fr) * 2003-04-23 2006-01-18 Yuyama Mfg. Co., Ltd. Systeme de gestion de medicament
WO2017158032A1 (fr) 2016-03-15 2017-09-21 Fresenius Kabi Deutschland Gmbh Procédé pour élaborer une préparation médicinale

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6070761A (en) * 1997-08-22 2000-06-06 Deka Products Limited Partnership Vial loading method and apparatus for intelligent admixture and delivery of intravenous drugs
WO2001039874A1 (fr) 1999-12-03 2001-06-07 Baxter International Inc. Procede et appareil regulant la strategie de confection de melanges pharmaceutiques
US20020077857A1 (en) * 2000-12-15 2002-06-20 Paul Seelinger Local medication scan code date repository (LMSCDR)
EP1616550A1 (fr) * 2003-04-23 2006-01-18 Yuyama Mfg. Co., Ltd. Systeme de gestion de medicament
WO2017158032A1 (fr) 2016-03-15 2017-09-21 Fresenius Kabi Deutschland Gmbh Procédé pour élaborer une préparation médicinale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BOULLATA JOSEPH I. ET AL: "Parenteral nutrition compatibility and stability: A comprehensive review", vol. 46, no. 2, 17 November 2021 (2021-11-17), US, pages 273 - 299, XP093029892, ISSN: 0148-6071, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/jpen.2306> DOI: 10.1002/jpen.2306 *

Similar Documents

Publication Publication Date Title
DE60029301T2 (de) Verfahren und Vorrichtung zum Kontrollieren der Strategie des Kompoundierens von pharmazeutischen Gemischen
DE10108251B4 (de) Verabreichung eines Medikaments mittels Mikro-Verkapselung
EP1881858B1 (fr) Dispositif pour piloter une pluralite de pompes a perfusion
DE60107472T2 (de) Verbesserungen in datenverwaltungssystemen
DE10335116B4 (de) Integrierte elektronische Authentifizierung für die Freigabe von Softwareobjekten für ein Prozesssteuerungssystem
EP2542276A1 (fr) Système et méthode d&#39;administration de médicaments à un patient
DE102008056013A1 (de) Patientenbehandlungsplanungssystem
DE10049393A1 (de) Extracorporales Blutbehandlungssystem
EP3137204B1 (fr) Systeme et procédé pour préparer des compositions de pharmacie pour les ordonnances individuelles
WO2025051941A1 (fr) Procédé de production d&#39;une composition nutritionnelle parentérale ou entérale, système conçu pour celui-ci, et produit informatique
DE102015114766A1 (de) Vorrichtung und Verfahren zur Herstellung einer Lösung
EP1465687B2 (fr) Cartouche pour produire un concentre pour dialyse d&#39;acetate a partir d&#39;un precurseur de concentre fortement densifie et procedure pour le traitement de cartouche
EP2696836B1 (fr) Utilisation d&#39;un dispositif et d&#39;un procédé pour préparer des mélanges de substances pharmaceutiques
EP2768303B1 (fr) Procédé pour remplir au moins un réservoir
WO2019121962A1 (fr) Procédé servant à fabriquer des crèmes de manière automatisée
EP3107019A1 (fr) Procédé, produit-programme informatique et système d&#39;échange de données médicales
EP2195758B1 (fr) Système de transport et procédé pour l&#39;administration d&#39;un mélange de solutions médicamenteuses
EP3645105A1 (fr) Système de dialyse péritonéale
EP0977497A2 (fr) Procede de mise en marche d&#39;une installation de dosage de liquide a proprietes en ligne, notamment dans le cadre de la production de boissons gazeuses a base d&#39;eau, de sirop et de gaz carbonique
DE60120458T2 (de) Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen
DE10351732A1 (de) Konfiguration einer Injektionsvorrichtung
DE102018005193A1 (de) Verfahren zum Betrieb eines Medizingeräts und nach dem Verfahren arbeitendes Medizingerät
EP3492395B1 (fr) Dispositif et procédé destinés au remplissage dosé de récipients à l&#39;aide d&#39;un produit de remplissage
EP2065822B1 (fr) Procédé et système destinés au reconditionnement de médicaments
EP3782096B1 (fr) Contrôle de prise réalisé indépendamment du lieu

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24765486

Country of ref document: EP

Kind code of ref document: A1